M
M. Andreeff
Researcher at University of Texas MD Anderson Cancer Center
Publications - 50
Citations - 2870
M. Andreeff is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 27, co-authored 50 publications receiving 2747 citations. Previous affiliations of M. Andreeff include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.
TL;DR: MS-5 stromal cells prevented apoptosis in HL-60 cells and in primary AML blasts via modulation of Bcl-2 family proteins through up-regulating anti-apoptotic proteins in leukemic blasts.
Journal ArticleDOI
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Eli Estey,Peter F. Thall,M. Andreeff,M. Beran,Hagop M. Kantarjian,Susan O'Brien,Susan Escudier,L. E. Robertson,Charles Koller,Steve Kornblau +9 more
TL;DR: On average, G-CSF before, during, and after FA had no effect on CR or infection rates in this population, in which elderly patients and poor prognostic factors were prevalent.
Journal ArticleDOI
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid
M. Andreeff,Shuwei Jiang,Xinna Zhang,Marina Konopleva,Zeev Estrov,Virginia Snell,Zhong Xie,M. F. Okcu,Gisela Sanchez-Williams,J. Dong,Eli Estey,R. C. Champlin,Steve Kornblau,John C. Reed,Shourong Zhao +14 more
TL;DR: Surprisingly, low Bcl-2 content was associated with poor survival in a group of patients with poor prognosis cytogenetics and the development of new therapeutic strategies for AML are discussed.
Journal ArticleDOI
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
Shourong Zhao,Marina Konopleva,Marina Konopleva,Maria Cabreira-Hansen,Maria Cabreira-Hansen,Zhong Xie,Zhong Xie,Wei Hu,M. Milella,M. Milella,Zeev Estrov,Gordon B. Mills,M. Andreeff,M. Andreeff +13 more
TL;DR: The data suggest that the inhibition of the PI3K/AKT signaling pathway restores apoptosis in AML and may be explored as a novel target for molecular therapeutics inAML.
Journal ArticleDOI
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
Wan Zhang,Marina Konopleva,Vivian Ruvolo,Teresa McQueen,Randall L. Evans,William G. Bornmann,James A. McCubrey,Jorge E. Cortes,M. Andreeff +8 more
TL;DR: The studies demonstrated that sorafenib significantly inhibited the phosphorylation levels of Raf downstream target proteins MEK1/2 and Erk, induced apoptosis and inhibited colony formation in AML cell lines and in primary AML samples, and strongly suggest potential activity of sorAFenib as a novel mechanism-based therapeutic agent inAML.